Response of short-term cultures derived from human malignant glioma to aziridinylbenzoquinone, etoposide and doxorubicin: An in vitro phase II trial

Anti-Cancer Drugs

Volumn 12, Issue 9, 2001, Pages 753-760

  Darling, John L ^a   Thomas, David G T ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Astrocytoma; Aziridinylbenzoquinone; Chemosensitivity; Doxorubicin; Etoposide; Oligodendroglioma

Indexed keywords

AZIRIDINYLBENZOQUINONE; DOXORUBICIN; ETOPOSIDE;

ARTICLE; ASTROCYTOMA; CANCER CELL CULTURE; CHEMOSENSITIVITY; DRUG EFFICACY; GLIOMA; HUMAN; HUMAN CELL; OLIGODENDROGLIOMA; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AZIRIDINES; BENZOQUINONES; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; ETOPOSIDE; GLIOMA; HUMANS; TUMOR CELLS, CULTURED;

EID: 0034778352     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200110000-00007     Document Type: Article

References (44)

1. Primary central nervous system tumors of the supratentorial compartment
2. Brain and nervous system
3. Structure-antitumor activity relationships among quinone derivatives
4. Mechanisms of drug absorption and excretion. Passage of drugs in and out of the central nervous system
5. Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 1
6. Potential central nervous system antitumor agents. Aziridinylbenzoquinones
7. Potential CNS antitumor agents VI: Aziridinylbenzoquinones III
8. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2,5-diaziridinyl-3,6-bis (carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas
9. Intracerebral penetration and tissue distribution of 2,5-diaziridinyl-3,6-bis(carboethoxyamino) 1,4-benzoquinone (AZQ, NSC-182986)
10. A phase II trial of 2,5-diaziridinyl 3,6-bis (carboethoxyamino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors
11. EPEG, a new antineoplastic epipodophyllotoxin
12. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors
13. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability
14. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer
15. Adriamycin in the treatment of relapsed primary malignant brain tumours
16. Chemosensitivity in childhood brain tumours in vitro: Evidence of differential sensitivity to CCNU and vincristine
17. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain
18. Assay of anticancer drugs in tissue culture: Comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma
19. Radioisotopic quantitation in microtitration plates by an autofluorographic method
20. Scintillation autofluorographic assessment of isotope uptake in human glioma cells grown on microtitration plates using sodium salicylate
21. Neuronal and glial tumours in vitro: An overview
22. Interrelationship between differentiation and malignancy-associated properties in glioma
23. Patterns of the early, gross chromosomal changes in malignant human gliomas
24. Chromosome and chromosomal progression of human gliomas in vivo, in vitro and in athymic nude mice
25. Chromosomal evolution in malignant human gliomas starts with specific and usually numerical deviations
26. Markers of the malignant glial phenotype
27. Invasiveness of human glioma cell lines in vitro: Relation to tumorigenicity in athymic mice
28. Stimulation of extracellular matrix components in the normal brain by invading glioma cells
29. Treatment of patients with recurrent primary brain tumors with AZQ
30. Effect of AZQ (1,4-cyclohexadiene-1,4-diacarbamic acid-2,5-bis(1-aziridinyl)-3,6-dioxodiethylester) in recurring supratentorial malignant brain gliomas - A phase II study
31. Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A Phase II study by the Illinois Cancer Council
32. Phase II diaziquone based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms
33. Phase I trial and pharmacokinetics of aziridinylbenzoquinone (NSC 182986) in humans
34. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
35. 6-methylguanine-DNA methyltransferase in tumors and cells of the oligodendrocyte lineage
36. High-dose etoposide in the treatment of relapsed primary brain tumors
37. Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma
38. Etoposide (VP-16-213) in malignant brain tumors: A phase II study
39. Therapy for patients with high grade astrocytoma using intraarterial chemotherapy and radiation therapy
40. Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification
41. Developing new methods for the treatment of malignant brain tumours: Local delivery of anti-neoplastic agents using biodegradable polymers
42. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas
43. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors